A breast MRI report follows a standardized structure built around two core questions: what does the finding look like (its shape and borders), and how does it behave when contrast dye flows through it (how quickly it lights up and fades). Understanding these two dimensions, morphology and enhancement kinetics, is the key to reading any breast MRI result. Every report also ends with a BI-RADS score from 0 to 6, which is the single most important number to focus on because it translates all the technical findings into a clear risk category and a recommended next step.
What a Breast MRI Report Contains
A standard breast MRI report opens with clinical context: your history, why the scan was ordered, and any prior imaging for comparison. It then describes the MRI technique used and what type of image processing was applied. The body of the report covers breast tissue composition, background enhancement levels, and then the main findings, including the type, size, and location of any lesions. It closes with a BI-RADS assessment category.
Breast tissue composition is described the same way as on a mammogram: fatty, scattered fibroglandular tissue, heterogeneously dense, or extremely dense. This tells you how much glandular tissue is present, which affects how the images look overall.
Background Parenchymal Enhancement
Before describing any specific findings, the radiologist notes how much your normal breast tissue “lights up” after contrast dye is injected. This is called background parenchymal enhancement, or BPE, and it falls into four levels: minimal (25% or less of glandular tissue enhances), mild (25 to 50%), moderate (50 to 75%), or marked (over 75%). Higher BPE is more common in younger women and can lead to more areas being flagged for closer review, which sometimes means additional imaging or callbacks.
If your report mentions moderate or marked BPE, you might worry it makes the scan less reliable. Research from the American Journal of Roentgenology found that sensitivity for detecting cancer was 90.9% in women with moderate or marked BPE compared to 95.7% in those with minimal or mild levels, a difference that was not statistically significant. In other words, the scan remains highly effective regardless of your BPE level.
The Three Types of Findings
When something enhances (lights up with contrast) beyond the normal background, the radiologist classifies it into one of three categories: a focus, a mass, or non-mass enhancement. Each one is described differently and carries different implications.
Focus
A focus is a tiny dot of enhancement, typically under 5 millimeters, that is too small to characterize further. It often turns out to be a bit of normal enhancing tissue. If it appears new or doesn’t match findings on other imaging, the radiologist may recommend a short-term follow-up scan.
Mass
A mass is a three-dimensional, space-occupying lesion with visible borders. The report describes three features of every mass. Shape is classified as round, oval, lobulated, or irregular. Margin describes the border: smooth, irregular, or spiculated (jagged, finger-like projections). Internal enhancement pattern describes how contrast fills the mass: homogeneous (uniform), heterogeneous (uneven), rim enhancement (bright edges with a darker center), or with internal septations (dividing walls).
Certain combinations raise more concern than others. A round or oval mass with smooth margins and homogeneous enhancement is more likely benign. An irregular mass with spiculated margins and rim enhancement is far more suspicious. Your radiologist weighs all three descriptors together rather than any single feature in isolation.
Non-Mass Enhancement
Non-mass enhancement, or NME, is an area that lights up but doesn’t form a distinct lump with clear borders. Instead of shape and margins, the report describes its distribution pattern: focal, linear, segmental (wedge-shaped, following a duct system), regional, or diffuse. It also describes the internal pattern of enhancement: homogeneous, heterogeneous, clumped, or clustered-ring. Segmental distribution and clumped internal enhancement are the patterns most associated with malignancy, particularly ductal carcinoma in situ.
Enhancement Kinetic Curves
This is where breast MRI goes beyond what a mammogram or ultrasound can show. After contrast dye is injected, the scanner captures images at multiple time points to track how quickly a finding enhances and what happens to that signal over time. The resulting pattern is plotted as a kinetic curve, and there are three types.
Type 1 (persistent): Signal intensity keeps rising steadily over time. In one well-known study, this pattern was seen in 83% of benign lesions and only 9% of cancers. A persistent curve is reassuring.
Type 2 (plateau): Signal rises initially, then flattens out and stays level. This is the most ambiguous pattern. Research shows it appears in roughly 34% of malignant lesions and 13% of benign ones. A plateau curve typically prompts the radiologist to weigh the morphological features more heavily to decide the next step.
Type 3 (washout): Signal rises quickly, then drops. This is the most concerning pattern. A multicenter study of nearly 1,000 breast lesions found that 76% of lesions showing washout were malignant, and a washout curve carried five times the cancer risk compared to a persistent curve. In another study, this pattern appeared in 57% of cancers but only 6% of benign findings.
Radiologists combine the kinetic curve with the morphological description. A mass with suspicious shape and a washout curve is highly concerning. A smooth, oval mass with a persistent curve is almost certainly benign. When the morphology and kinetics point in different directions, the report will usually err on the side of caution.
The BI-RADS Score
Every breast MRI report ends with a BI-RADS category, a number from 0 to 6 that summarizes the findings and tells you (and your doctor) what should happen next. The American College of Radiology released an updated BI-RADS v2025 manual, which remains the current standard across mammography, ultrasound, and MRI.
- BI-RADS 0: The scan is incomplete. Additional imaging is needed before a score can be assigned.
- BI-RADS 1: Negative. The breasts appear normal and symmetrical with no suspicious findings. Continue routine screening.
- BI-RADS 2: Benign. The radiologist noted something, such as a cyst, a stable fibroadenoma, or post-surgical changes, but it shows no signs of cancer. Continue routine screening.
- BI-RADS 3: Probably benign, with a 2% or lower chance of malignancy. Follow-up imaging is recommended every six to twelve months for at least two years to confirm stability.
- BI-RADS 4: Suspicious. A biopsy is recommended. This category is subdivided: 4A carries a likelihood of malignancy between 2% and 10%, 4B between 10% and 50%, and 4C between 50% and 95%.
- BI-RADS 5: Highly suggestive of cancer, with at least a 95% chance of malignancy. A biopsy is strongly recommended.
- BI-RADS 6: Known cancer, already confirmed by a previous biopsy. This category is used when MRI is performed to guide treatment planning.
If your report says BI-RADS 1 or 2, there is nothing to worry about. A BI-RADS 3 means something was seen but is overwhelmingly likely to be benign; the follow-up imaging is a precaution, not an alarm. BI-RADS 4 and 5 mean tissue sampling is needed to get a definitive answer.
Common Benign Findings
Breast MRI scanners produce high-resolution, thin-slice images that pick up far more detail than mammograms. This means reports frequently mention findings that are entirely normal or harmless. Cysts, which appear bright on certain sequences because they are fluid-filled, are among the most common. Fibroadenomas, solid but benign growths, also show up regularly. Intramammary lymph nodes, small immune-system nodes located within the breast tissue, are detected in roughly 31% of breast MRIs and are almost always reactive (responding to normal immune activity) rather than concerning.
You may also see mentions of incidental findings outside the breast, such as small liver cysts or thyroid nodules, since the scan captures some surrounding anatomy. These are typically noted for completeness and rarely require any action.
How MRI Compares to Other Imaging
Breast MRI has a sensitivity between 81% and 100% for detecting cancer, roughly double that of mammography. In a meta-analysis comparing the two directly, MRI detected cancer 77% of the time versus 39% for mammography. The trade-off is specificity: MRI’s ranges from 83% to 98%, meaning it is more likely to flag something that turns out to be benign. This is why MRI reports sometimes lead to additional imaging or biopsies that ultimately show no cancer.
Specificity improves significantly after your first scan. In studies tracking women over multiple screening rounds, MRI specificity climbed from around 90% in the first round to 97% in subsequent rounds. This happens because the radiologist can compare new images to your prior ones, making it much easier to distinguish stable, benign findings from new or changing ones. Ultrasound adds no additional detection benefit when MRI is already being used.
Understanding the Image Sequences
Your report may reference specific imaging sequences by name. T1-weighted images show the basic anatomy of fat and glandular tissue, providing a structural map of the breast. T2-weighted images with fat suppression make fluid appear bright, which is how radiologists identify cysts and distinguish them from solid lesions. STIR sequences suppress the fat signal entirely, making it easier to spot areas of swelling or fluid collection.
The most diagnostically important sequence is the dynamic contrast-enhanced series, where gadolinium-based contrast dye is injected and images are captured at multiple time points. This is the sequence that generates the kinetic curves and reveals how blood flows through a finding. Cancers tend to develop abnormal, leaky blood vessels that grab contrast quickly and release it quickly, producing the fast uptake and washout pattern that radiologists look for. Benign tissue, by contrast, typically enhances slowly and gradually over time.